X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (448) 448
Publication (22) 22
Book / eBook (11) 11
Book Review (5) 5
Conference Proceeding (5) 5
Magazine Article (3) 3
Book Chapter (2) 2
Newspaper Article (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (203) 203
index medicus (185) 185
female (129) 129
male (125) 125
adult (106) 106
middle aged (106) 106
dermatology (93) 93
melanoma (90) 90
aged (69) 69
oncology (55) 55
psychiatry (54) 54
analysis (52) 52
treatment outcome (52) 52
internet (47) 47
depression (44) 44
melanoma - pathology (43) 43
psychotherapy (40) 40
young adult (40) 40
aged, 80 and over (39) 39
psychology (39) 39
clinical trials (37) 37
skin (36) 36
skin neoplasms - pathology (33) 33
cancer (32) 32
cognitive-behavioral therapy (32) 32
melanoma - drug therapy (32) 32
mental health (29) 29
care and treatment (28) 28
adolescent (27) 27
skin cancer (27) 27
anxiety (26) 26
psychology, clinical (25) 25
animals (24) 24
efficacy (24) 24
malignant-melanoma (24) 24
medicine & public health (24) 24
mental depression (23) 23
retrospective studies (23) 23
diagnosis (22) 22
mental disorders (22) 22
metastasis (22) 22
metastatic melanoma (22) 22
skin neoplasms - drug therapy (22) 22
emotion regulation (21) 21
ipilimumab (21) 21
cost-effectiveness (20) 20
intervention (20) 20
metaanalysis (20) 20
risk factors (20) 20
medicine (19) 19
survival (19) 19
dk/atira/pure/core/keywords/600089002 (18) 18
emotions (18) 18
antineoplastic agents - therapeutic use (17) 17
cell biology (17) 17
depression - therapy (17) 17
immunology (17) 17
medical informatics (17) 17
melanoma - genetics (17) 17
melanoma - metabolism (17) 17
randomized controlled trial (17) 17
randomized controlled-trial (17) 17
surveys and questionnaires (17) 17
cognitive therapy (16) 16
depression, mental (16) 16
further section (16) 16
germany (16) 16
major depressive disorder (16) 16
original paper (16) 16
prevention (16) 16
social sciences (16) 16
tumors (16) 16
clinical psychology (15) 15
major depression (15) 15
management (15) 15
medical research (15) 15
medicine, research & experimental (15) 15
meta-analysis (15) 15
mutation (15) 15
prevalence (15) 15
prospective studies (15) 15
research (15) 15
studies (15) 15
dk/atira/pure/core/keywords/559092180 (14) 14
health care sciences & services (14) 14
mental-health (14) 14
prognosis (14) 14
psychiatry and mental health (14) 14
skin diseases (14) 14
skin neoplasms - genetics (14) 14
cognitive therapy - methods (13) 13
cost-benefit analysis (13) 13
disorders (13) 13
health sciences (13) 13
medicine, experimental (13) 13
melanoma - mortality (13) 13
patients (13) 13
primary-care (13) 13
psychological treatments (13) 13
study protocol (13) 13
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 2015, Volume 51, Issue 18, pp. 2792 - 2799
Abstract Background Acquired resistance to BRAF inhibitors (BRAFi) is a near-universal phenomenon caused by numerous genetic and non-genetic alterations. In... 
Hematology, Oncology and Palliative Medicine | Resistance | Vemurafenib | NRAS | Splice | Acquired | Dabrafenib | BRAF | MEK1 | MAPK | Meta-analysis | SURVIVAL | RAF INHIBITION | METASTATIC MELANOMA | THERAPY | ONCOLOGY | PATHWAY | COBIMETINIB | B-RAF | MUTATIONS | Skin Neoplasms - drug therapy | United States | Humans | Middle Aged | Melanoma - enzymology | Male | Antineoplastic Agents - therapeutic use | Skin Neoplasms - enzymology | Time Factors | DNA Mutational Analysis | Melanoma - genetics | Skin Neoplasms - mortality | Biomarkers, Tumor - metabolism | Female | Biomarkers, Tumor - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - metabolism | Skin Neoplasms - pathology | Genetic Predisposition to Disease | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Melanoma - pathology | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Phenotype | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Biomarkers, Tumor - genetics | Mutation | Australia | Melanoma - mortality | splice | vemurafenib | meta-analysis | resistance | amplification | spectrum | MEK2 | dabrafenib | acquired
Journal Article
Journal Article
British Journal of Dermatology, ISSN 0007-0963, 10/2005, Volume 153, Issue 4, pp. 733 - 739
Journal Article
Cancer Discovery, ISSN 2159-8274, 01/2014, Volume 4, Issue 1, pp. 94 - 109
Journal Article
Journal Article
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2015, Volume 26, Issue 6, pp. 1238 - 1244
Background: Recent evidence suggests that ionizing radiation may be associated with unexpected side-effects in melanoma patients treated with concomitant BRAF... 
Dabrafenib | Vemurafenib | Braf | Radiosensitization | Radiotherapy | Radiation | MULTICENTER | MUTATION-POSITIVE MELANOMA | vemurafenib | BRAF | OPEN-LABEL | COMBINATION | METASTATIC MELANOMA | SKIN TOXICITY | ONCOLOGY | radiation | radiosensitization | radiotherapy | CUTIS-VERTICIS-GYRATA | dabrafenib | RADIATION RECALL DERMATITIS | Oximes - adverse effects | Humans | Middle Aged | Radiation Tolerance | Melanoma - enzymology | Oximes - therapeutic use | Male | Protein Kinase Inhibitors - adverse effects | Radiosurgery - adverse effects | Whole-Body Irradiation - adverse effects | Feasibility Studies | Radiation-Sensitizing Agents - therapeutic use | Young Adult | Skin Neoplasms - enzymology | Time Factors | Aged, 80 and over | Adult | Female | Retrospective Studies | Imidazoles - therapeutic use | Proto-Oncogene Proteins B-raf - metabolism | Radiodermatitis - etiology | Skin Neoplasms - pathology | Chemoradiotherapy - methods | Skin Neoplasms - therapy | Europe | Imidazoles - adverse effects | Treatment Outcome | Radiodermatitis - prevention & control | Melanoma - pathology | Radiation-Sensitizing Agents - adverse effects | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Indoles - adverse effects | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Melanoma - therapy | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 07/2018, Volume 98, pp. 10 - 16
Journal Article
ANNALS OF ONCOLOGY, ISSN 0923-7534, 03/2014, Volume 25, Issue 3, pp. 747 - 753
Since the majority of melanomas eventually become resistant and progress, combining selective BRAF inhibitors (BRAFi) with immunotherapies has been proposed to... 
treatment | IMMUNITY | CELLS | lymphocytes | INHIBITION | ONCOLOGY | vemurafenib | SUBSETS | melanoma | BRAF | T cells | dabrafenib | Oximes - adverse effects | Humans | Middle Aged | Leukocyte Common Antigens - biosynthesis | Oximes - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Receptors, CCR7 - biosynthesis | Lymphocyte Subsets - immunology | CD4-Positive T-Lymphocytes - immunology | Interleukin-9 - biosynthesis | Young Adult | Antineoplastic Agents - adverse effects | Leukocytes, Mononuclear - immunology | Aged, 80 and over | Adult | Female | Retrospective Studies | Imidazoles - therapeutic use | Leukocytes, Mononuclear - drug effects | Cytokines - metabolism | Lymphocyte Subsets - drug effects | Imidazoles - adverse effects | Cells, Cultured | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Vemurafenib | Indoles - adverse effects | Sulfonamides - therapeutic use | L-Lactate Dehydrogenase - blood | Protein Kinase Inhibitors - therapeutic use | CD8-Positive T-Lymphocytes - drug effects | Melanoma - drug therapy | Lymphocyte Count | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | CD8-Positive T-Lymphocytes - immunology | CD4-Positive T-Lymphocytes - drug effects | Interferon-gamma - biosynthesis | Melanoma - mortality | Original
Journal Article